GlassScriptPhysician profile
Jillian K Mcangus
NPI 1285011502
$11,454.53
in general payments reported to CMS, 2019-2025
23 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,184 · 2020: $298 · 2021: $2,361 · 2022: $1,702 · 2023: $1,352 · 2024: $1,150 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,768 · Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,768.23 |
| Food and Beverage | $1,140.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $3,190.72 | 2019-2025 | Avenir, Comprehensive Shoulder System, Gps III Platelet Concentration System |
| Exactech, INC. | $2,362.76 | 2019 | |
| Arthrex, INC. | $1,847.00 | 2021 | |
| Stryker Corporation | $1,792.23 | 2019-2025 | Mako, Tornier Perform Anatomic Augmented Glenoid, Insignia |
| Pylant Medical | $1,312.45 | 2019-2021 | |
| Pacira Therapeutics, INC. | $152.88 | 2020-2021 | |
| Medtronic, INC. | $142.66 | 2023 | Corevalve Evolut R |
| Si-Bone, INC. | $127.25 | 2019 | |
| Amgen INC. | $117.95 | 2020-2024 | Krystexxa |
| Depuy Synthes Sales INC. | $56.62 | 2021-2024 | Monovisc |
| Astrazeneca Pharmaceuticals LP | $52.10 | 2022 | |
| Ethicon US, LLC | $48.83 | 2022-2024 | Stratafix, Ethicon |
| Heron Therapeutics, INC. | $44.60 | 2021-2024 | Zynrelef |
| Bioventus LLC | $34.88 | 2020-2024 | Gelsyn-3 |
| Horizon Therapeutics Plc | $33.53 | 2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $27.92 | 2020-2025 | Euflexxa |
| Molnlycke Health Care US, LLC | $21.92 | 2022 | |
| Baudax Bio INC. | $18.98 | 2020 | |
| Vericel Corporation | $14.71 | 2022 | |
| Osteomed LLC | $14.61 | 2020 | |
| Radius Health, INC. | $14.46 | 2020 | |
| Arthrosurface Incorporated | $14.43 | 2025 | Ovomotion |
| Janssen Pharmaceuticals, INC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Mcangus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.